In 1956, a team of researchers launched the first multi‐institutional randomized clinical trial in oncology. Known as "Protocol \#1," this study compared continuous versus intermittent dosing of metrotrexate when combined with 6‐mercaptopurine for the treatment of children and adults with acute leukemia. The trial arose out of work initiated at the National Cancer Institute (NCI) by James "Jim" Holland and Lloyd Law. Jim had arrived at the NCI Cancer Chemotherapy National Service Center immediately after completing his fellowship at Delafield Hospital, a cancer hospital associated with Columbia University College of Physicians and Surgeons, where he had received his M.D. degree. At the NCI, Jim used data obtained from Law\'s murine leukemia models to justify human studies of combination chemotherapy, a practice that was widely condemned by the academic hematology establishment of the time. The result was Protocol \#1, which was co‐authored by Jim Holland, Emil "Tom" Frei, then at the NCI, and George Selkirk at Buffalo Children\'s Hospital. This study was the first protocol of a new research consortium that went on to become the Cancer and Leukemia Group B (CALGB), now the Alliance for Clinical Trials in Oncology (Alliance). James F. Holland and Jimmie Corker Hollandimage

Another transformative event of 1956 was the marriage of Jim Holland to Jimmie Coker. Jimmie was a psychiatrist who received her M.D. from Baylor College of Medicine, followed by postdoctoral training at Washington University and the Massachusetts General Hospital. In 1956, she joined Jim in his move from the NCI to the State University of New York, Buffalo. While Jim served as Chief of Roswell Park Memorial Institute\'s Department of Medicine A, Jimmie joined the faculty of the SUNY Buffalo Department of Psychiatry. Jimmie was the first to fully recognize the profound effect of a cancer diagnosis on the psychological and social well‐being of patients and their families. In her work to understand and mitigate the harmful life‐altering effects of cancer, Jimmie founded the entirely new field of psycho‐oncology. Jim and Jimmie Holland became the most impactful couple in all of oncology: Jim working to save lives by developing new therapies, and Jimmie working to ensure the quality of the lives that were saved or lengthened.

Throughout their long careers, Jim and Jimmie Holland were treasured members of the Alliance. Jim co‐founded CALGB along with Tom Frei, M.D., and served as CALGB Group Chair from 1963 to 1981. In 2011, as a part of an NCI‐mandated consolidation, CALGB joined with the North Central Cancer Treatment Group and the American College of Surgeons Oncology Group to become the Alliance. Because CALGB was the largest and longest‐running of the three groups, many advocated for the new group to retain this name. When I asked Jim his opinion on the matter, I received a characteristic response: "Who cares what the heck you call it, as long as you get the work done!" After the transition to the Alliance, Jim remained active in the breast committee, where he advocated for studies to validate a viral etiology for breast cancer. He also served on the Alliance Board of Directors until his death on March 22, 2018, at age 92.

During Jim\'s tenure as CALGB Group Chair, Jimmie convinced him to start a psychiatry committee, and the field of psycho‐oncology grew out of data that this committee acquired by adding quality‐of‐life studies to CALGB treatment trials. Jimmie was responsible for developing tools that allow caregivers to respond to the needs of cancer patients, including the recognition of "distress" as the sixth vital sign, along with temperature, respiration, pulse, blood pressure, and pain. Under her leadership, CALGB conducted the first two formal psychosocial studies in oncology. Her importance to the group is recognized by the annual Jimmie C. Holland, M.D., Lecture, now in its 18th year. At the time of her death, on December 24, 2017, at age 89, Jimmie was overseeing a project to implement psycho‐oncology research and training in low‐resource countries. image

Jim and Jimmie had many spectacular accomplishments and adventures during their long lives. They raised six wonderful children together in a home that was characterized by a special combination of intellectual wealth and warm‐hearted whimsy. From 1972 to 1973, Jim and Jimmie and their six small children lived in Moscow, where they represented the U.S. government in a program to forge new ties with the people of the Soviet Union. In Russia, Jim studied oncology research and lectured on drug development using animal cancer models, and Jimmie was a consultant to the Psychiatric Research Institute of Moscow. Returning to the U.S., Jim became the founding Chair of the Department of Neoplastic Diseases at Mount Sinai in New York City. In 1972, Jim shared the Albert Lasker Clinical Medical Research Award for proving that combination chemotherapy could cure cancer. Jimmie became the Chair of the Department of Psychiatry and Behavioral Sciences at Memorial Sloan‐Kettering Cancer Center, the first woman to chair a department at this institution. She founded the International Psycho‐oncology Society and the American Psycho‐oncology Society and was a Fellow of the Institute of Medicine of the U.S. In later years, Jim and Jimmie became concerned over the disparities in cancer care in countries with limited resources and founded the African Organization for Research and Training in Cancer (AORTIC). This group works to support, integrate, and facilitate evidence‐based interventions to achieve prevention and control of cancer in Africa. image

I suspect that my relationship with Jim and Jimmie mirrors that of so many of their junior colleagues. The job of CALGB and now Alliance Group Chair, which is the responsibility that I have had over the past 8 years, involves many challenges, and often difficult decisions must be made. I always felt supported and encouraged by Jim and Jimmie and grateful that they continued to be so involved in our work. They understood the unique stresses and anxieties of leadership. "What you\'re doing is hard, keep at it, you\'re doing fine!" they would tell me. Jim and Jimmie Holland continued their work until the time of their deaths this winter, within 3 months of each other. At the time of their passing, the 5‐year survival rate for acute leukemia, all types combined, had gone from essentially zero in 1956 to roughly 80% for children and 55% for adults. In addition, an army of professionals now provides care for cancer patients using an approach that understands and responds to both their physical and emotional needs. These two remarkable people share the credit for saving and immeasurably enriching so many lives. They also bequeath to cancer patients a legacy of devotion to ending suffering due to this terrible disease that will be carried on by the many trainees who have been inspired by their example.
